Christine E Cherella, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Nodule | 10 | 2022 | 750 | 2.460 |
Why?
|
| Thyroid Neoplasms | 11 | 2022 | 2282 | 2.200 |
Why?
|
| Adenocarcinoma, Follicular | 3 | 2022 | 324 | 1.760 |
Why?
|
| Thyroid Gland | 6 | 2021 | 1173 | 1.100 |
Why?
|
| Congenital Hypothyroidism | 1 | 2020 | 39 | 0.720 |
Why?
|
| Thyroidectomy | 3 | 2022 | 879 | 0.720 |
Why?
|
| Cytodiagnosis | 2 | 2022 | 435 | 0.650 |
Why?
|
| Sentinel Surveillance | 1 | 2018 | 281 | 0.560 |
Why?
|
| Iodine | 1 | 2018 | 286 | 0.550 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 250 | 0.550 |
Why?
|
| Hypothyroidism | 1 | 2018 | 658 | 0.460 |
Why?
|
| Infant, Premature, Diseases | 1 | 2018 | 706 | 0.430 |
Why?
|
| Ultrasonography | 4 | 2021 | 5985 | 0.420 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 1094 | 0.300 |
Why?
|
| Contrast Media | 1 | 2018 | 5300 | 0.260 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2022 | 101 | 0.210 |
Why?
|
| Child | 12 | 2022 | 77709 | 0.200 |
Why?
|
| Hashimoto Disease | 1 | 2022 | 97 | 0.200 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2022 | 224 | 0.180 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2021 | 111 | 0.180 |
Why?
|
| Thyrotropin | 2 | 2022 | 849 | 0.180 |
Why?
|
| Injections, Intralymphatic | 1 | 2018 | 15 | 0.170 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 1032 | 0.170 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 286 | 0.150 |
Why?
|
| Thyroid Diseases | 1 | 2021 | 379 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2018 | 588 | 0.150 |
Why?
|
| Thyroxine | 1 | 2020 | 667 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2020 | 591 | 0.130 |
Why?
|
| Radiology Information Systems | 1 | 2019 | 523 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2020 | 25625 | 0.130 |
Why?
|
| Adolescent | 9 | 2022 | 85781 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 2924 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2019 | 1915 | 0.110 |
Why?
|
| Threonine | 1 | 2014 | 279 | 0.110 |
Why?
|
| Infant | 3 | 2020 | 35136 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 783 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2014 | 563 | 0.100 |
Why?
|
| Serine | 1 | 2014 | 826 | 0.090 |
Why?
|
| Prognosis | 2 | 2022 | 29063 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2021 | 3474 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 1486 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2022 | 77449 | 0.090 |
Why?
|
| Tyrosine | 1 | 2014 | 1461 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2019 | 41006 | 0.090 |
Why?
|
| Humans | 16 | 2022 | 744343 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2018 | 2044 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2020 | 3444 | 0.070 |
Why?
|
| Male | 10 | 2022 | 350118 | 0.070 |
Why?
|
| Logistic Models | 1 | 2021 | 13408 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 56430 | 0.070 |
Why?
|
| Female | 10 | 2022 | 380194 | 0.070 |
Why?
|
| Adult | 4 | 2022 | 214055 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 40561 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18370 | 0.050 |
Why?
|
| Insulin | 1 | 2014 | 6580 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 23338 | 0.040 |
Why?
|
| Pregnancy | 1 | 2018 | 29144 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 63114 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 1770 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 1142 | 0.030 |
Why?
|
| Anisomycin | 1 | 2014 | 28 | 0.030 |
Why?
|
| Thapsigargin | 1 | 2014 | 104 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 12959 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3271 | 0.030 |
Why?
|
| Tunicamycin | 1 | 2014 | 112 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 104 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 2035 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 816 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 2593 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 1406 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
| Cricetinae | 1 | 2014 | 2472 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2014 | 846 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 5179 | 0.020 |
Why?
|
| Radiology | 1 | 2019 | 2100 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 213383 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2503 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15076 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 2109 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 3475 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2022 | 12720 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13284 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 2938 | 0.010 |
Why?
|
| Prevalence | 1 | 2021 | 15226 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2014 | 4026 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 3798 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14722 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
| United States | 2 | 2021 | 69872 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 2872 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12745 | 0.010 |
Why?
|
| Rats | 1 | 2014 | 24260 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 72290 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 23403 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168757 | 0.000 |
Why?
|